期刊文献+

缺氧状态下人胰腺癌细胞对吉西他滨反应的实验研究

Hypoxia increase the resistance of human pancreatic cancer cells to gemcitabine chemotherapy
下载PDF
导出
摘要 目的:观察缺氧状态对人胰腺癌细胞吉西他滨化疗敏感性的影响并分析其相关机制。方法:将人胰腺癌细胞SW1990分为常氧组、缺氧组、常氧+吉西他滨组和缺氧+吉西他滨组。MMT法检测各组细胞增殖、流式细胞仪检测细胞凋亡、Real-time PCR和Western blot分别检测缺氧诱导因子-1α(HIF-1α)、多药耐药基因(MDR-1)mRNA和蛋白的表达。结果:与常氧+吉西他滨组相比,低氧+吉西他滨组的细胞增殖率明显增加,细胞凋亡率显著下降(P<0.05);低氧组和低氧+吉西他滨组HIF-1α蛋白表达分别显著高于常氧组(P<0.05或P<0.01);与常氧组相比,低氧组和低氧+吉西他滨组的MDR1 mRNA和蛋白表达水平均显著升高(P<0.05或P<0.01)。结论:缺氧状态可增加人胰腺癌细胞SW1990对吉西他滨的化疗抵抗,其机制与缺氧环境可诱导HIF-1α和MDR1基因表达有关。 Objective:To observe the impact of the hypoxic state of human pancreatic carcinoma cell on gemcitabine chemosensitivity and the mechanism. Methods: SW1990 pancreatic cancer ceils were divided into normoxic group,hypoxia group, normoxic plus gemcitahine group, and hypoxia plus gemcitabine group. Cell proliferation were detected by MMT and apoptosis were detected by flow cytometry. Real -time PCR and Western blot were used to detect hypoxia - inducible factor - 1 α ( HIF - 1 α ) , the multidrug resistance gene ( MDR - 1 ) mRNA and protein expression. Results: The proliferation rate of hypoxia + gemcitabine group compared to the normoxia plus gemcitabine group was significantly increased and the apoptotic rate was significantly decreased (P 〈 0.05 ). H/F - 1α protein expression in hypoxia group and hypoxia + gemcitabine group were significantly higher than the normoxic group ( P 〈 0.05 or P 〈 0.01 ). Compared with normoxic group, MDR1 mRNA and protein significantly increased in hypoxie group and hypoxia + gemcitabine group (P 〈0.05 or P 〈 0.01 ). Conclusion: Hypoxia can increase chemotherapy resistance to gemcitabine of SW1990 pancreatic cancer cell, and it was caused by HIF - Ice and MDR1 gene expression induced by hypoxic environment.
出处 《现代肿瘤医学》 CAS 2013年第4期720-723,共4页 Journal of Modern Oncology
基金 复旦大学上海医学院青年骨干科研启动基金(编号:11L-3)
关键词 缺氧 缺氧诱导因子-1Α 多药耐药基因 胰腺癌 化疗 hypoxia hypoxia - inducible factor - 1 α multidrug resistance gene pancreatic cancer chemotheranv
  • 相关文献

参考文献10

  • 1Melillo G. Inhibiting hypoxia - inducible factor 1 for cancer therapy [ J ]. Mol Cancer Re,2006,4 ( 9 ) :601 - 605.
  • 2Ding Z, Yang L, Xie X. Expression and significance of hypoxia - in- ducible factor - 1 alpha and MDRI/P - glycoprotein inhuman colon carcinoma tissue and cells[ J]. J Cancer Res Clin Onco1,2010,136 ( 11 ) : 1697 - 1707.
  • 3Livak K J, Sehmittgen TD. Analysis of relative gene expression data using real -time quantitative PCR and the 2( -Delta DeltaC (T)) [ J ]. Method Method,2001,25 (4) :402 - 408.
  • 4Poon E, Harris AL, Ashcroft M. Targeting the hypoxia- inducible factor (HIF) pathway in cancer[ J]. Expert Rev Mol Med,2009, 11 :e26.
  • 5张威浩,裘正军,胡志前,孙晶.HIF-1α及多药耐药相关基因在结肠癌中的表达及意义[J].中国癌症杂志,2007,17(11):875-878. 被引量:8
  • 6Seifeddine R, Dreiem A, Blanc E, et al. Hypoxia down - regtdates CCAAT/enhancer binding protein - alpha expression in breast cancer cells[J]. Cancer Re,2008,68(7) :2158 -2165.
  • 7Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia - inducible factor - 1 - dependent regulation of the multidrug resistance ( MDR1 ) gene[ J]. Cancer Re,2002,62(12) :3387 -3394.
  • 8Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF -kappaB [ J ]. J Clin Invest,2001, 107(3) :241 -246.
  • 9Gillet JP, Efferth T, Remacle J. Chemotherapy - induced resistance by ATP - binding cassette transporter genes [ J ]. Bioehim Biophys Acta,2007,1775 (2) :237 - 262.
  • 10Zhu Z, Wang Y, Liu Z, et al. Inhibitory effects of epigallocatechin - 3 - gaUate on cell proliferation and the expression of HIF - 1 ct and P - gp in the human pancreatic carcinoma cell line PANG - 1 [ J ]. Oncol Rep,2012,27 (5) : 1567 - 1572.

二级参考文献12

  • 1Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies [J]. Cancer Treat Rev, 2003, 29(4):297-307.
  • 2Goethals L, Debucquoy A, Perneel C, et al. Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers [ J ]. Int J Radiat Oncol Biol Phys, 2006, 65( 1 ) :246-254.
  • 3Mizukami Y, Fujiki K, Duerr EM, et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc [ J ]. J Biol Chem, 2006, 281(20):13957-13963.
  • 4Abramovitch R, Tavor E, Jacob-Hirsch J, et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression [J]. Cancer Res, 2004, 64(4) :1338-1346.
  • 5Ruiz Gomez M J, Souviron Rodriguez A, Martinez Morillo M. P-glycoprotein, a membrane pump that represents a barrier to chemotherapy in cancer patients [ J ]. An Med Interna, 2002, 19(9) : 477-485.
  • 6Kruh GD, Belinshy MG. The MRP family of drug efflux pumps [ J ]. Oncogene,2003, 22 (47) : 7537-7552.
  • 7Xu J, Liu Y, Yang Y, et al. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2 [ J]. J Biol Chem,2004, 279(19) : 19781-19789.
  • 8Bartolini G, Orlandi M, Papi A, et al. A search for muhidrug resistance modulators : the effects of retinoids in human colon carcinoma cells [J]. In Vivo, 2006, 20(6A):729-733.
  • 9Gregg LS. Targeting HIF-1 for cancer therapy [ J]. Nature Rev, 2003, 3 : 721-732.
  • 10Tanimoto K, Makino Y, Pereira T, et al. Mechanism of regulation of the hypoxia-inducible factor-1 alpaha by the vonhippel-Lindau tumor suppressor protein [J]. EMBO J, 2000, 19:4298- 4309.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部